Genetic Engineering Immune Response Protein Scientist 
Drug Discovery World
FEBRUARY 3, 2023
One of these candidates is VSV-SUDV, developed and tested by scientists at NIH’s National Institute of Allergy and Infectious Diseases in Hamilton, Montana. In the current studies, the investigators replaced the key EBOV protein in Ervebo with the comparable protein from SUDV.
Drug Discovery World
JULY 5, 2023
A fulfilling part of my job is meeting the scientists, companies, and institutions at the forefront of ground-breaking research that are advancing patient health outcomes. For example, if a patient’s tumour has a particular protein present, called a checkpoint protein, this will reduce the response of T-cells.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
NOVEMBER 8, 2023
Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.
Cloudbyz
MARCH 5, 2024
Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells. Mode of Action : Small Molecules: They often work by binding to specific sites on target proteins to inhibit or activate their function, which can affect various biological pathways inside the cell.
pharmaphorum
MARCH 10, 2021
The study suggests that serum taken from patients injected with the mRNA shot, also known as BNT162b2, was able to neutralise a genetically engineered version of SARS-CoV-2 with the P.1 1 mutations, as well as variants from the UK and South Africa. That work in the Manaus area, where the variant first emerged, has estimated that P.1
The Pharma Data
JUNE 1, 2022
Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. Previous research has shown that caspase 11 in mice has many of the same immune-response functions as caspase 4 in humans.
Drug Discovery World
JULY 22, 2022
By Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences. As a result, researchers are striving to continually improve immuno-oncology approaches using the patient’s own immune cells to combat tumours. Courtney Ferrebee, PhD, is a field applications scientist at Taconic Biosciences. After earning a B.A.
Expert insights. Personalized for you.
52 
Let's personalize your content